Jeffrey M. Leiden

2014 - Vertex Pharmaceuticals

In 2014, Jeffrey M. Leiden earned a total compensation of $36.6M as Chairman, President & CEO at Vertex Pharmaceuticals, a 179% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$2,970,000
Option Awards$12,669,261
Salary$1,100,000
Stock Awards$19,883,350
Other$12,857
Total$36,635,468

Leiden received $19.9M in stock awards, accounting for 54.27% of the total pay in 2014.

Leiden also received $3M in non-equity incentive plan, $12.7M in option awards, $1.1M in salary and $12.9K in other compensation.

Rankings

In 2014, Jeffrey M. Leiden's compensation ranked 34th out of 12,981 executive pay records tracked by us. In other words, Leiden earned more than 99.7% of all executives tracked by us in 2014.

ClassificationRankingPercentile
All
34
out of 12,981
100th
Manufacturing
Division
9
out of 4,954
100th
Chemicals And Allied Products
Major group
3
out of 1,653
100th
Drugs
Industry group
3
out of 1,327
100th
Pharmaceutical Preparations
Industry
3
out of 1,017
100th
Source: SEC filing on April 28, 2017.

Leiden's colleagues

We found four more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2014.

2014

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2014

Stuart Arbuckle

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2014

Jeffrey Chodakewitz

Vertex Pharmaceuticals

Chief Medical Officer

2014

Kenneth Horton

Vertex Pharmaceuticals

Chief Legal Officer

News

You may also like